Rukmini Rajagopalan

Summary

Publications

  1. ncbi request reprint Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis
    Rukmini Rajagopalan
    Takeda Pharmaceuticals North America, Inc, Lincolnshire, Illinois 60069, USA
    Clin Ther 26:1400-10. 2004
  2. ncbi request reprint Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone
    R Rajagopalan
    Takeda Pharmaceuticals North America, Inc, Lincolnshire, IL 60069, USA
    Diabetes Obes Metab 7:161-9. 2005
  3. ncbi request reprint The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials
    Rukmini Rajagopalan
    Takeda Pharmaceutical North America, Inc, Lincolnshire, IL, USA
    Am J Geriatr Pharmacother 4:123-33. 2006
  4. ncbi request reprint Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials
    Rukmini Rajagopalan
    Takeda Pharmaceuticals North America, Inc, 475 Half Day Road, Lincolnshire, IL 60069, USA
    Curr Med Res Opin 21:163-72. 2005
  5. ncbi request reprint Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus
    Rukmini Rajagopalan
    Takeda Pharmaceuticals North America Inc, Lincolnshire, Illinois, USA
    Drugs Aging 21:259-71. 2004
  6. ncbi request reprint Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: a retrospective data analysis
    Rajesh Balkrishnan
    Division of Management and Policy Sciences, University of Texas School of Public Health, Houston, TX 77030, USA
    Curr Med Res Opin 20:1633-40. 2004
  7. ncbi request reprint Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population
    Iftekhar Kalsekar
    College of Pharmacy and Health Sciences, Butler University, 4600 Sunset Ave, Indianapolis, Indiana 46208, USA
    J Manag Care Pharm 12:121-9. 2006
  8. ncbi request reprint Outcomes associated with introduction of thiazolidinedione therapy in Medicaid enrolled patients with type 2 diabetes: an updated and expanded retrospective analysis
    Rajesh Balkrishnan
    Department of Pharmacy Practice and Administration, Ohio State University, Columbus, Ohio 43210, USA
    Curr Med Res Opin 22:551-9. 2006
  9. ncbi request reprint Economic impact of cardiovascular co-morbidity in patients with type 2 diabetes
    Reema Mody
    TAP Pharmaceutical Products Inc, Lake Forest, IL 60045, USA
    J Diabetes Complications 21:75-83. 2007
  10. ncbi request reprint Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study
    Rajesh Balkrishnan
    Department of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
    Clin Ther 25:2958-71. 2003

Detail Information

Publications11

  1. ncbi request reprint Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis
    Rukmini Rajagopalan
    Takeda Pharmaceuticals North America, Inc, Lincolnshire, Illinois 60069, USA
    Clin Ther 26:1400-10. 2004
    ..However, concerns have been raised regarding the association between TZD use and a heightened risk for congestive heart failure (CHF)...
  2. ncbi request reprint Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone
    R Rajagopalan
    Takeda Pharmaceuticals North America, Inc, Lincolnshire, IL 60069, USA
    Diabetes Obes Metab 7:161-9. 2005
    ..The aim of this study was to assess the incidence of liver failure in association with antidiabetic treatment using pioglitazone vs. other oral antidiabetic medications...
  3. ncbi request reprint The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials
    Rukmini Rajagopalan
    Takeda Pharmaceutical North America, Inc, Lincolnshire, IL, USA
    Am J Geriatr Pharmacother 4:123-33. 2006
    ..This analysis was conducted to evaluate the impact of pioglitazone (PIO), both as monotherapy and as part of combination therapy, on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes...
  4. ncbi request reprint Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials
    Rukmini Rajagopalan
    Takeda Pharmaceuticals North America, Inc, 475 Half Day Road, Lincolnshire, IL 60069, USA
    Curr Med Res Opin 21:163-72. 2005
    ..To evaluate the effect of pioglitazone, metformin, and/or sulfonylurea on metabolic syndrome and its component parameters after a year of treatment...
  5. ncbi request reprint Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus
    Rukmini Rajagopalan
    Takeda Pharmaceuticals North America Inc, Lincolnshire, Illinois, USA
    Drugs Aging 21:259-71. 2004
    ..Pioglitazone as monotherapy and in combination with sulfonylurea, metformin, or insulin has consistently demonstrated improved glycaemic and lipid parameters in patients with type 2 diabetes mellitus...
  6. ncbi request reprint Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: a retrospective data analysis
    Rajesh Balkrishnan
    Division of Management and Policy Sciences, University of Texas School of Public Health, Houston, TX 77030, USA
    Curr Med Res Opin 20:1633-40. 2004
    ..In addition differences among the TZDs with respect to these outcomes were examined...
  7. ncbi request reprint Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population
    Iftekhar Kalsekar
    College of Pharmacy and Health Sciences, Butler University, 4600 Sunset Ave, Indianapolis, Indiana 46208, USA
    J Manag Care Pharm 12:121-9. 2006
    ..To compare health care utilization and costs for type 2 diabetes patients initiating therapy with one of two thiazolidinediones (TZDs, pioglitazone or rosiglitazone) or insulin in a Medicaid population...
  8. ncbi request reprint Outcomes associated with introduction of thiazolidinedione therapy in Medicaid enrolled patients with type 2 diabetes: an updated and expanded retrospective analysis
    Rajesh Balkrishnan
    Department of Pharmacy Practice and Administration, Ohio State University, Columbus, Ohio 43210, USA
    Curr Med Res Opin 22:551-9. 2006
    ....
  9. ncbi request reprint Economic impact of cardiovascular co-morbidity in patients with type 2 diabetes
    Reema Mody
    TAP Pharmaceutical Products Inc, Lake Forest, IL 60045, USA
    J Diabetes Complications 21:75-83. 2007
    ..To evaluate the impact of cardiovascular co-morbidity on total and diabetes-related healthcare costs in patients with type 2 diabetes...
  10. ncbi request reprint Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study
    Rajesh Balkrishnan
    Department of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
    Clin Ther 25:2958-71. 2003
    ....
  11. ncbi request reprint Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain
    Kit N Simpson
    Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Clin Drug Investig 27:807-17. 2007
    ....